Cynata Therapeutics Ltd V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ltd

<< Previous

Bullboard Posts

Next >>

Post by Golfing9to5on Jul 11, 2020 1:52pm

136 Views

Post# 31255709

Greenbills

Yes great job. Maybe you can be on the marketing team for Cypress. For some reason I'm thinking Cypress wants to keep this low-key for a while so others can still buy in.
Anyways great job for trying to bring some more eyes to this project Greenbills!!

<< Previous

Bullboard Posts

Next >>

Grid Battery Metals sets spin-off date for AC/DC Battery shares